CFRXQ (ContraFect) OCF Yield %: 0.00 (As of Jul. 02, 2026)


What is ContraFect OCF Yield %?

ContraFect CFRXQ -90.00% OCF Yield % is 0.00 as of Jul. 02, 2026.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, ContraFect's Trailing 12-Month Cash Flow from Operations is $-35.59 Mil, and Market Cap is $0.00 Mil. Therefore, ContraFect's OCF Yield % for today is 0.00%.

The historical rank and industry rank for ContraFect's OCF Yield % or its related term are showing as below:


During the past 11 years, the highest OCF Yield % of ContraFect was 1012333.33%. The lowest was -8742300.00%. And the median was %.

CFRXQ's OCF Yield % is not ranked *
in the Biotechnology industry.
Industry Median: -8.13
* Ranked among companies with meaningful OCF Yield % only.

ContraFect's OCF Margin % for the quarter that ended in Sep. 2023 was %.

ContraFect OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

ContraFect OCF Yield % Related Terms

ContraFect OCF Yield % Historical Data

* Premium members only.

The historical data trend for ContraFect's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ContraFect OCF Yield % Chart

ContraFect Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.67 -28.77 -23.61 -39.73 -1,006.08

ContraFect Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -583.99 -872.55 -1,228.01 -203.05 -567.99

ContraFect OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

ContraFect's OCF Yield % for the fiscal year that ended in Dec. 2022 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-45.974 / 4.5696
=-1,006.08%

ContraFect's annualized OCF Yield % for the quarter that ended in Sep. 2023 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-8.669 * 4 / 6.1050615
=-567.99%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of 0.00 mean?
ContraFect (CFRXQ) has a OCF Yield % of 0.00 as of Jul. 02, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on ContraFect and its competitors.
Is ContraFect's OCF Yield % too high?
ContraFect's current OCF Yield % is 0.00.
How does ContraFect's OCF Yield % compare to ADTX and RUBY?
ContraFect's OCF Yield % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on ContraFect and its competitors. ContraFect's current OCF Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ContraFect stock overvalued right now?
ContraFect (CFRXQ) has a current OCF Yield % of 0.00. The current OCF Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For ContraFect (CFRXQ), the current OCF Yield % is 0.00 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ContraFect Business Description

Address 28 Wells Avenue, 3rd Floor, Yonkers, NY, USA, 10701
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.